2.Matteo Bargagli, Andri Vetsch, Manuel A Anderegg, et al. Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients, Nephrology Dialysis Transplantation. Oct 29, 2022;, gfac298....
Do not drink grapefruit juice during treatment with JYNARQUE. This could cause you to have too much tolvaptan in your blood. Themost common side effectsof JYNARQUE are: thirst and increased fluid intake making large amounts of urine, urinating often, and urinating at night ...
2、徐德超, 马熠熠, 梅长林. 托伐普坦治疗快速进展型常染色体显性多囊肾病的临床实践指南解读[J]. 中华肾脏病杂志, 2019, 35(5):387-392. 3、ChebibFouadT,Perrone Ronald D,Chapman Arlene B et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.[J] .J. Am. Soc. Nep...
Vertex 计划本月在健康志愿者中启动 VX-407 的 1 期临床试验。 "The advancement of VX-407, a first-in-class molecule for the treatment of ADPKD, into the clinic represents another important opportunity to transform the treatment of a serious disease," said Carmen Bozic, M.D., Executive Vice ...
Treatment of persistent gross hematuria with tranexamic acid in autosomal dominant polycystic kidney disease[J]. Kidney Blood Press Res, 2017, 42(1): 156-164. DOI: 10.1159/000474961.[36] 马熠熠, 陈冬平, 梅长林, 等. 常...
Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 RGLS8429 治疗后尿中多囊藻素 1 (PC1) 在统计学上显著增加 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD 尿多囊藻毒素在 ADPKD 患者中表现出...
University of California, Los Angeles, LosAngeles, California; and8 Division of Nephrology, University of Maryland School of Medicine, Baltimore, MarylandABSTRACTIn the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) hasbeen limited to the management of its symptoms and com...
Untapped Potential of the ADPKD Treatment Landscapedoi:10.1681/ASN.2024xhj53kpaJennifer LafaveEllie McclatchyBridget BerganMeghan WeissAmerican Society of NephrologyJournal of the American Society of Nephrology
3. Autosomal Dominant Polycystic Kidney Disease Current Treatment Patterns 4. Autosomal Dominant Polycystic Kidney Disease - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. Autosomal Dominant Polycystic Kidney Disease Late-Stage Products (Phase-III) ...
Tolvaptan由大塚在日本發現,如獲得FDA核准,將成為ADPKD的首個治療藥物,ADPKD是一種遺傳性基因疾病,目前沒有治療藥物 大塚開發tolvaptan用於治療ADPKD顯示該公司致力於因應未獲治療或治療不足的疾病,這些疾病傳統上不是藥廠優先關注的重點